New Two-Drug attack targets Tough-to-Treat lung cancer
NCT ID NCT07017829
Summary
This study is testing whether adding a new drug called GT103 to an existing immunotherapy (pembrolizumab) can better control advanced lung cancer that has a specific genetic change (STK11 mutation). The trial is for patients whose cancer has continued to grow despite prior treatment with pembrolizumab. Researchers will see if this combination can stop cancer progression for longer and is safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Roswell Park Cancer Institute
RECRUITINGBuffalo, New York, 14263, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.